Resende Fernando Francisco Borges, Titze-de-Almeida Simoneide Souza, Titze-de-Almeida Ricardo
Technology for Gene Therapy Laboratory, Central Institute of Sciences, Faculty of Agronomy and Veterinary Medicine, University of Brasilia, Brasília 70910-900, Brazil.
Oncol Lett. 2018 Apr;15(4):4891-4899. doi: 10.3892/ol.2018.7917. Epub 2018 Feb 1.
Astrocytic tumors, including astrocytomas and glioblastomas, are the most common type of primary brain tumors. Treatment for glioblastomas includes radiotherapy, chemotherapy with temozolomide (TMZ) and surgical ablation. Despite certain therapeutic advances, the survival time of patients is no longer than 12-14 months. Cancer cells overexpress the neuronal isoform of nitric oxide synthase (nNOS). In the present study, it was examined whether the nNOS enzyme serves a role in the damage of astrocytoma (U251MG and U138MG) and glioblastoma (U87MG) cells caused by TMZ. First, TMZ (250 µM) triggered an increase in oxidative stress at 2, 48 and 72 h in the U87MG, U251MG and U138MG cell lines, as revealed by 2',7'-dichlorofluorescin-diacetate assay. The drug also reduced cell viability, as measured by MTT assay. U87MG cells presented a more linear decline in cell viability at time-points 2, 48 and 72 h, compared with the U251MG and U138MG cell lines. The peak of oxidative stress occurred at 48 h. To examine the role of NOS enzymes in the cell damage caused by TMZ, N(ω)-nitro-L-arginine methyl ester (L-NAME) and 7-nitroindazole (7-NI) were used. L-NAME increased the cell damage caused by TMZ while reducing the oxidative stress at 48 h. The preferential nNOS inhibitor 7-NI also improved the TMZ effects. It caused a 12.8% decrease in the viability of TMZ-injured cells. Indeed, 7-NI was more effective than L-NAME in restraining the increase in oxidative stress triggered by TMZ. Silencing nNOS with a synthetic small interfering (si)RNA (siRNAnNOShum_4400) increased by 20% the effects of 250 µM of TMZ on cell viability (P<0.05). Hoechst 33342 nuclear staining confirmed that nNOS knock-down enhanced TMZ injury. In conclusion, our data reveal that nNOS enzymes serve a role in the damage produced by TMZ on astrocytoma and glioblastoma cells. RNA interference with nNOS merits further studies in animal models to disclose its potential use in brain tumor anticancer therapy.
星形细胞瘤,包括星形细胞瘤和胶质母细胞瘤,是最常见的原发性脑肿瘤类型。胶质母细胞瘤的治疗方法包括放射治疗、替莫唑胺(TMZ)化疗和手术切除。尽管在治疗方面取得了一定进展,但患者的生存时间仍不超过12 - 14个月。癌细胞过度表达神经元型一氧化氮合酶(nNOS)。在本研究中,检测了nNOS酶在TMZ引起的星形细胞瘤(U251MG和U138MG)和胶质母细胞瘤(U87MG)细胞损伤中是否起作用。首先,2',7'-二氯荧光素二乙酸酯检测显示,TMZ(250 μM)在2、48和72小时时引发U87MG、U251MG和U138MG细胞系氧化应激增加。该药物还降低了细胞活力,通过MTT检测法测定。与U251MG和U138MG细胞系相比,U87MG细胞在2、48和72小时时间点的细胞活力呈现出更线性的下降。氧化应激峰值出现在48小时。为了检测NOS酶在TMZ引起的细胞损伤中的作用,使用了N(ω)-硝基-L-精氨酸甲酯(L-NAME)和氯硝基吲唑(7-NI)。L-NAME增加了TMZ引起的细胞损伤,同时在48小时时降低了氧化应激。优先的nNOS抑制剂7-NI也增强了TMZ的作用。它使TMZ损伤细胞的活力降低了12.8%。实际上,在抑制TMZ引发的氧化应激增加方面,7-NI比L-NAME更有效。用合成的小干扰(si)RNA(siRNAnNOShum_4400)沉默nNOS可使250 μM TMZ对细胞活力的影响增加20%(P<0.05)。Hoechst 33342核染色证实nNOS敲低增强了TMZ损伤。总之,我们的数据表明nNOS酶在TMZ对星形细胞瘤和胶质母细胞瘤细胞产生的损伤中起作用。对nNOS进行RNA干扰值得在动物模型中进一步研究,以揭示其在脑肿瘤抗癌治疗中的潜在用途。